A Familial Analysis of Familial Hyperlipidemia Attributed to the Y2184C Mutation of the APOB Gene

Clin Lab. 2025 Jan 1;71(1). doi: 10.7754/Clin.Lab.2024.240751.

Abstract

Background: Familial hyperlipidemia (familial hypercholesterolemia, FH) is an autosomal genetic disorder. It includes type heterozygous familial hyperlipidemia (heterozygous familial hypercholesterolemia). HeFH is mainly caused by mutations in the LDLR, APOB, and PCSK9 genes and is characterized by elevated plasma low-density lipoprotein cholesterol levels.

Methods: We present a case of HeFH attributed to an APOB gene mutation. The whole-genome DNA of peripheral blood was extracted from the blood of the proband and their parents, and the exons of peripheral blood were sequenced through high-throughput sequencing. The selected mutation sites were verified by sequencing using the Sanger method.

Results: A heterozygous mutation, c.6551A>G (p.Y2184C), in exon 26 of the APOB gene (Chr2-21233189) was identified in both the proband and the mother. Combined with the clinical features, HeFH caused by this mutation was initially considered.

Conclusions: For patients with a high degree of clinical suspicion of FH, a definitive diagnosis should be established through genetic testing, enabling patients to receive early treatment and effectively prevent the occurrence of cardiovascular events.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Apolipoprotein B-100 / genetics
  • DNA Mutational Analysis
  • Female
  • Genetic Predisposition to Disease
  • Genetic Testing / methods
  • Heterozygote
  • Humans
  • Hyperlipoproteinemia Type II* / blood
  • Hyperlipoproteinemia Type II* / diagnosis
  • Hyperlipoproteinemia Type II* / genetics
  • Male
  • Middle Aged
  • Mutation*
  • Pedigree*

Substances

  • APOB protein, human
  • Apolipoprotein B-100